Additionally, scholars build relationships with diverse STEM professionals by attending field trips and fireside chats at New Jersey companies such as Bristol Myers Squibb, Kenvue, Panasonic, PSEG, Stryker and United Airlines.

Source: https://unionnewsdaily.com/news/county/union-county-students-named-2023-2024-governors-stem-scholars

As a group, equities analysts expect that Bristol-Myers Squibb will post 7.43 earnings per share for the current fiscal year.

Source: https://www.etfdailynews.com/2023/09/30/cornerstone-advisory-llc-sells-392-shares-of-bristol-myers-squibb-nysebmy/

Atlantic Securities increased their price target on Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd.

Source: https://www.americanbankingnews.com/2023/05/01/765-shares-in-bristol-myers-squibb-nysebmy-purchased-by-glass-jacobson-investment-advisors-llc.html

Bank of America upped their price target on Bristol-Myers Squibb from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, April 21st.

Source: https://www.americanbankingnews.com/2023/06/23/central-bank-trust-co-has-557000-position-in-bristol-myers-squibb-nysebmy.html

Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $63.

Source: https://www.etfdailynews.com/2023/12/02/bryn-mawr-capital-management-llc-buys-2542-shares-of-bristol-myers-squibb-nysebmy/

Berenberg Bank lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and decreased their target price for the company from $82.00 to $76.00 in a research note on Wednesday, September 14th.

Source: https://www.americanbankingnews.com/2023/01/05/capital-investment-counsel-inc-trims-stake-in-bristol-myers-squibb-nysebmy.html

Bing was set on not letting another drag flick get past her as she saved two Penny Squibb efforts in a row early in the fourth quarter.

Source: https://www.perthnow.com.au/sport/field-hockey/late-lawton-goal-clinches-hockeyroos-win-over-usa-c-9939901

Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Scotia Capital Inc.

Source: https://www.etfdailynews.com/2023/10/28/bristol-myers-squibb-nysebmy-shares-purchased-by-scotia-capital-inc/

Catalyst Financial Partners LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.5% in the first quarter.

Source: https://www.americanbankingnews.com/2023/06/23/central-bank-trust-co-has-557000-position-in-bristol-myers-squibb-nysebmy.html

Coppell Advisory Solutions Corp. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $31,000.

Source: https://www.etfdailynews.com/2023/12/09/bristol-myers-squibb-nysebmy-shares-sold-by-kolinsky-wealth-management-llc/

Envestnet Asset Management Inc. increased its position in shares of Bristol-Myers Squibb by 193.4% in the first quarter.

Source: https://www.etfdailynews.com/2023/09/30/cornerstone-advisory-llc-sells-392-shares-of-bristol-myers-squibb-nysebmy/

Finally, Live Oak Investment Partners bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $33,000.

Source: https://www.etfdailynews.com/2023/12/29/hunter-perkins-capital-management-llc-has-5-47-million-position-in-bristol-myers-squibb-nysebmy/

Finally, McClarren Financial Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $41,000.

Source: https://www.americanbankingnews.com/2023/03/25/altus-wealth-group-llc-makes-new-investment-in-bristol-myers-squibb-nysebmy.html

Hennessy Advisors Inc. decreased its stake in shares of Bristol-Myers Squibb () by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC.

Source: https://www.dailypolitical.com/2023/12/28/bristol-myers-squibb-nysebmy-position-lowered-by-hennessy-advisors-inc.html

I believe Bristol Myers Squibb () is a very good example of this.

Source: https://seekingalpha.com/article/4568461-allianz-2-ways-to-view-play-still-buy?source=feed_all_articles

Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.

Source: https://www.prnewswire.com/news-releases/germany-cell-and-gene-therapy-market---focused-insights-2023-2028-sector-to-reach-3-44-billion-by-2028-at-a-40-cagr-301784069.html

On average, equities analysts predict that Bristol-Myers Squibb will post 7.6 earnings per share for the current year.

Source: https://www.etfdailynews.com/2023/01/09/assenagon-asset-management-s-a-has-6-35-million-holdings-in-bristol-myers-squibb-nysebmy/

Pharmaceutical giant Bristol Myers Squibb has selected IPG’s Mediabrands to lead U.S media buying and planning for its brands, according to multiple people close to the situation.

Source: https://adage.com/article/agency-news/bristol-myers-squibb-awards-430-million-us-media-business-ipgs-mediabrands/2494846

Principal Street Partners LLC cut its holdings in shares of Bristol-Myers Squibb () by 4.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission.

Source: https://www.etfdailynews.com/2023/12/13/bristol-myers-squibb-nysebmy-shares-sold-by-principal-street-partners-llc/

Specifically, Bristol-Myers Squibb is exposed to potential IRA price negotiation pressures for its major drugs including Eliquis, Opdivo, and Orencia; although I do not yet model IRA-driven price pressure as I would like to await further developments.

Source: https://seekingalpha.com/article/4637617-bristol-myers-squibb-looks-grossly-overvalued-loe-dragging-topline?source=feed_all_articles